Their AI-powered platform offers fast, personalized medical advice and can help determine the best course of action for managing GLP-1 side effects
It may be beneficial for patients with conditions that are associated with oxidative stress, such as neurodegenerative diseases, certain cancers, and liver diseases
A key reason for the success of its Zepbound drug is its status as a "dual agonist." Wegovy targets only GLP-1 receptors, whereas tirzepatide (aka Zebound) targets both GLP-1 and GIP receptors, leading to greater overall weight loss
Were left wondering, How are GLP-1s causing these effects? asks senior author Marc Montminy, MD, PhD, a biochemist, physiologist, and distinguished professor emeritus at Salk